1
|
Cehelyk EK, Syed ZA. Long-term outcomes of corneal crosslinking. Curr Opin Ophthalmol 2024; 35:315-321. [PMID: 38700950 DOI: 10.1097/icu.0000000000001054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2024]
Abstract
PURPOSE OF REVIEW This manuscript summarizes contemporary research from 2018 to 2023 evaluating long-term (≥2 years) outcomes of corneal crosslinking (CXL) for progressive keratoconus (KCN). RECENT FINDINGS The standard Dresden protocol (SDP) has been utilized clinically since the early 2000 s to treat ectatic disorders, primarily progressive KCN and postrefractive ectasia. Various modifications have since been introduced including accelerated and transepithelial protocols, which are aimed at improving outcomes or reducing complications. This review summarizes data demonstrating that the SDP halts disease progression and improves various visual and topographic indices (UDVA, CDVA, Kmax, K1, K2) up to 13 years postoperatively. Accelerated and transepithelial protocols have been found to be well tolerated alternatives to SDP with similar efficacy profiles. Studies focusing on pediatric populations identified overall higher progression rates after CXL. All protocols reviewed had excellent safety outcomes in adults and children. SUMMARY Recent studies revealed that SDP successfully stabilizes KCN long term, and a variety of newer protocols are also effective. Pediatric patients may exhibit higher progression rates after CXL. Further research is required to enhance the efficacy and ease of these protocols.
Collapse
Affiliation(s)
| | - Zeba A Syed
- Cornea Service, Wills Eye Hospital, Philadelphia, Pennsylvania, USA
| |
Collapse
|
2
|
Bordais J, Cassagne M, Touboul D, Saunier V, Butterworth J, Malecaze F, Soler V, Fournié P. Conventional Epithelial-Off Corneal Crosslinking in Patients With Progressive Keratoconus: 10-Year Outcomes. Cornea 2024; 43:00003226-990000000-00528. [PMID: 38537067 PMCID: PMC11142646 DOI: 10.1097/ico.0000000000003532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 11/23/2023] [Accepted: 01/29/2024] [Indexed: 06/02/2024]
Abstract
PURPOSE Corneal crosslinking (CXL) is the standard treatment of progressive keratoconus (KC). We evaluated the safety and 10-year outcomes of conventional "epithelial-off" CXL for progressive KC for the first time in a cohort in France. METHODS We conducted a retrospective review of patients undergoing conventional CXL (Dresden protocol) in our tertiary ophthalmology department from 2006 to 2011 with 10-year follow-up. The primary outcome was change in preoperative versus postoperative keratometry measured by maximum keratometry (Kmax), steep keratometry (K2), flat keratometry (K1), mean keratometry (Km), and topographic cylinder. Secondary outcomes were changes in visual and refractive outcomes. We report postoperative complications and adverse events. RESULTS Eighty-nine eyes from 76 patients (67% male patients, mean age 22.7 ± 7.6 years) were included. Mean Kmax (-2.31 ± 2.98 diopters (D); P < 0.00001), K2 (-2.07 ± 3.15 D; P < 0.00001), K1 (-1.00 ± 2.29 D; P = 0.00008), Km (-1.53 ± 2.47 D; P < 0.00001), and topographic cylinder (-1.15 ± 2.53 D; P = 0.00004) significantly decreased 10 years after CXL compared with preoperative baseline. Significant decreases were still observed between 5 and 10 years after for mean Kmax, mean K2, mean K1, and mean Km. Mean distance best spectacle-corrected visual acuity and mean manifest refraction spherical equivalent were significantly improved after 10 years versus before CXL. The 10-year rate of repeat CXL was n = 3/76 patients (4%) (all younger than 18 years at first CXL) and of loss of >3 lines in best spectacle-corrected visual acuity was n = 1/76 patients (1%). CONCLUSIONS Progressive KC was effectively stabilized with a prolonged flattening and maintenance of functional vision improvements after 10 years. Repeat CXL was rare and only required among younger patients.
Collapse
Affiliation(s)
- Jérémy Bordais
- Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, Toulouse, France
| | - Myriam Cassagne
- Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, Toulouse, France
- University of Toulouse III, Toulouse, France; and
| | - David Touboul
- Ophthalmology Department, Anterior Segment Unit, Bordeaux University Hospital, Bordeaux, France
| | - Valentine Saunier
- Ophthalmology Department, Anterior Segment Unit, Bordeaux University Hospital, Bordeaux, France
| | - Jacqueline Butterworth
- Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, Toulouse, France
| | - François Malecaze
- Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, Toulouse, France
- University of Toulouse III, Toulouse, France; and
| | - Vincent Soler
- Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, Toulouse, France
- University of Toulouse III, Toulouse, France; and
| | - Pierre Fournié
- Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, Toulouse, France
- University of Toulouse III, Toulouse, France; and
| |
Collapse
|
3
|
Vinciguerra R, Bordignon N, Ferraro V, Mazzotta C, Rosetta P, Vinciguerra P. Corneal Collagen Cross-Linking for Progressive Keratoconus in Pediatric Patients: Up to 14 Years of Follow-up. Am J Ophthalmol 2023; 255:170-177. [PMID: 37478962 DOI: 10.1016/j.ajo.2023.07.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Revised: 07/10/2023] [Accepted: 07/17/2023] [Indexed: 07/23/2023]
Abstract
PURPOSE To assess the long-term outcomes of corneal collagen cross-linking according to the Dresden protocol (S-CXL) in progressive pediatric keratoconus (KC). DESIGN Retrospective, single-center noncomparative interventional study. METHODS Patients aged <18 years who underwent S-CXL from June 2007 to January 2011 in Humanitas Clinical and Research Center, Rozzano, Milan, Italy, and completed at least 10 years of follow-up were included. Corrected distance visual acuity (CDVA), refraction, and tomography were evaluated at baseline and ≥10 years after S-CXL. Meeting 2 of the following 3 criteria indicated reprogression: progression above 95% CI for post-CXL population of A or B values or a decrease in minimal thickness C evaluated with the ABCD display. RESULTS Thirty-eight eyes of 24 patients fulfilled inclusion criteria. At a mean of 11.6 years postoperation (maximum 14 years), the CDVA improved significantly (from 0.703 ± 0.33 decimal fraction to 0.887 ± 0.2, P < .001). Similarly, the A value significantly improved from 2.550 ± 1.7 to 1.627 ± 1.68 (P = .019). Thirteen eyes (34%) showed significant postoperative progression in 2 of the 3 parameters A, B, and C. Of these, only 3 eyes (7.9%) of 3 patients showed a statistically significant change in the A value. CONCLUSIONS S-CXL proved to be a safe treatment for progressive KC in pediatric patients with an anterior curvature progression rate of up to 7.9% at ≥10 years of follow-up.
Collapse
Affiliation(s)
| | - Niccolò Bordignon
- Department of Biomedical Sciences, Humanitas University (N.B., V.F., P.V.), Milan
| | - Vanessa Ferraro
- Department of Biomedical Sciences, Humanitas University (N.B., V.F., P.V.), Milan
| | - Cosimo Mazzotta
- Departmental Ophthalmology Unit, USL Toscana Sud-Est, Campostaggia (C.M.); SienaSiena Crosslinking Center, Monteriggioni (C.M.), Siena
| | | | - Paolo Vinciguerra
- Department of Biomedical Sciences, Humanitas University (N.B., V.F., P.V.), Milan; Humanitas Clinical and Research Center, IRCCS (P.V.), Rozzano, Milan, Italy
| |
Collapse
|
4
|
Kollros L, Torres-Netto EA, Rodriguez-Villalobos C, Hafezi NL, Hillen M, Lu NJ, Hafezi F. Progressive keratoconus in patients older than 48 years. Cont Lens Anterior Eye 2023; 46:101792. [PMID: 36481131 DOI: 10.1016/j.clae.2022.101792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Revised: 11/24/2022] [Accepted: 11/29/2022] [Indexed: 12/12/2022]
Abstract
PURPOSE To report cases of progressive keratoconus (KC) in patients aged ≥48 years and the successful arrest of progression using corneal cross-linking (CXL) with riboflavin and ultraviolet-A light. OBSERVATIONS Five eyes from four patients with progressive KC aged 48, 48, 51 and 54 years are reported in this case series. All eyes were followed regularly after initial diagnosis. Kmax was used as an indicator of progression and KC progressed at a rate of 1.4 diopters in 6 months and 14.6 diopters in 14 months. All patients eventually received CXL, and all were aged ≥50 years at the time of the procedure. One eye required two CXL procedures to successfully stabilize the patient's cornea. CONCLUSION Despite the probability of KC progression strongly declining after the age of 40 years, it never becomes zero. It is therefore advisable to continue regular follow-up corneal tomography examinations in patients with KC, even in their fifth and sixth decades of life.
Collapse
Affiliation(s)
| | - Emilio A Torres-Netto
- ELZA Institute, Dietikon, Switzerland; Paulista School of Medicine, Federal University of Sao Paulo, Sao Paulo, Brazil; Faculty of Medicine, University of Geneva, Geneva, Switzerland; University of Zurich, CABMM, Laboratory for Ocular Cell Biology Group, Zurich, Switzerland
| | | | - Nikki L Hafezi
- ELZA Institute, Dietikon, Switzerland; School of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium
| | | | - Nan-Ji Lu
- ELZA Institute, Dietikon, Switzerland; School of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium; School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Farhad Hafezi
- ELZA Institute, Dietikon, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland; School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China; USC Roski Eye Institute, University of Southern California, Los Angeles, CA, USA; University of Zurich, CABMM, Laboratory for Ocular Cell Biology Group, Zurich, Switzerland
| |
Collapse
|
5
|
Raiskup F, Herber R, Lenk J, Ramm L, Wittig D, Pillunat LE, Spoerl E. Corneal Crosslinking With Riboflavin and UVA Light in Progressive Keratoconus: Fifteen-Year Results. Am J Ophthalmol 2023; 250:95-102. [PMID: 36736417 DOI: 10.1016/j.ajo.2023.01.022] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 01/18/2023] [Accepted: 01/19/2023] [Indexed: 02/04/2023]
Abstract
PURPOSE To analyze the 15-year results of corneal crosslinking (CXL) in progressive keratoconus. DESIGN Retrospective follow-up analysis of interventional study patients. METHODS This study included keratoconic eyes with progressive disease treated from 2001 to 2006 at the Department of Ophthalmology, Carl Gustav Carus University Hospital, TU Dresden, Germany. CXL was performed by applying riboflavin and ultraviolet A (UVA) light according to a standard protocol. The best-corrected distance visual acuity (BCVA), slitlamp examination, and corneal topography as well as corneal thickness values were recorded preoperatively and 15 years after the treatment. RESULTS A total of 42 eyes received a complete follow-up of 15 years. The mean age of the patients at baseline was 26.9 (95% CI: 25.0-28.8) years. The maximum keratometry was 61.6 (95% CI: 58.2 - 64.9) diopters (D) preoperatively and 55.1 (95% CI: 51.6-58.4) D postoperatively; the decrease was statistically significant (P < .001). The mean keratometry value changed from 50.3 (95% CI: 48.3-52.4) D to 47.5 (95% CI: 45.3-49.4) D (P < 0.001). Furthermore, the thinnest corneal thickness decreased statistically significantly by 40 (95% CI: 24-56) µm (P < .001). The BCVA improved statistically significantly from 0.4 to 0.2 logMAR after the treatment. Retreatment was needed in 14% of cases. Mild scarring of the superficial stromal corneal layers was observed in 36% of the eyes, and in 67% of them visual acuity was stable or even improved. CONCLUSIONS The CXL procedure proved to be an effective method in the treatment of keratoconic eyes in the progressive stage of the disease, and achieved long-term stabilization without the occurrence of serious complications or side effects.
Collapse
Affiliation(s)
- Frederik Raiskup
- From the Department of Ophthalmology, University Hospital Carl Gustav Carus, TU Dresden, Germany
| | - Robert Herber
- From the Department of Ophthalmology, University Hospital Carl Gustav Carus, TU Dresden, Germany.
| | - Janine Lenk
- From the Department of Ophthalmology, University Hospital Carl Gustav Carus, TU Dresden, Germany
| | - Lisa Ramm
- From the Department of Ophthalmology, University Hospital Carl Gustav Carus, TU Dresden, Germany
| | - Dierk Wittig
- From the Department of Ophthalmology, University Hospital Carl Gustav Carus, TU Dresden, Germany
| | - Lutz E Pillunat
- From the Department of Ophthalmology, University Hospital Carl Gustav Carus, TU Dresden, Germany
| | - Eberhard Spoerl
- From the Department of Ophthalmology, University Hospital Carl Gustav Carus, TU Dresden, Germany
| |
Collapse
|
6
|
Enders C, Vogel D, Dreyhaupt J, Wolf W, Garip-Kuebler A, Hall J, Neuhann L, Werner JU. Corneal cross-linking in patients with keratoconus: up to 13 years of follow-up. Graefes Arch Clin Exp Ophthalmol 2022; 261:1037-1043. [PMID: 36197498 DOI: 10.1007/s00417-022-05844-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Revised: 08/20/2022] [Accepted: 09/21/2022] [Indexed: 11/29/2022] Open
Abstract
INTRODUCTION To evaluate long-term safety and efficacy of corneal collagen cross-linking (CXL) in patients with keratoconus up to 13 years. MATERIALS AND METHODS In this mono-centre exploratory study, we included all consecutive patients who underwent CXL in our cornea centre from 01/01/2007 to 12/30/2011 and met the inclusion criteria. CXL was performed in all patients according to the Dresden protocol. Evaluation included best-corrected visual acuity (BCVA), topographic keratometry by Scheimpflug corneal tomography and endothelial cell count (ECC). Follow-up measurements were taken up to 13 years after treatment were compared with baseline values. RESULTS The study enrolled 168 eyes. The mean age of our patients was 26.3 years ± 7.8 years. A complete topographic dataset was available 1 year postoperatively for 142 eyes, 5 years postoperatively for 105 eyes, 10 years postoperatively for 61 eyes and 13 years postoperatively for 9 eyes. BCVA increased statistically significant after 1 year, 5 years and 10 years and non-significantly after 13 years. All keratometric parameters with exception of posterior astigmatism showed a statistically significant decrease after 1 year, 5 years and 10 years. After 13 years, the decrease was statistically significant only in Kmax, K2 and thinnest cornea. No significant changes in ECC were detected. Three eyes received Re-CXL, none of the eyes received penetrating keratoplasty and no infections occurred in this cohort. CONCLUSIONS CXL can slow down or even stop the progression of keratoconus in the majority of cases. The effect is long-lasting with excellent safety.
Collapse
Affiliation(s)
- Christian Enders
- MVZ Prof. Neuhann GmbH, Helene-Weber-Allee 19, 80637, Munich, Germany.
| | - Diana Vogel
- MVZ Prof. Neuhann GmbH, Helene-Weber-Allee 19, 80637, Munich, Germany
| | - Jens Dreyhaupt
- Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany
| | - Waltraud Wolf
- MVZ Prof. Neuhann GmbH, Helene-Weber-Allee 19, 80637, Munich, Germany.,MVZ Smileeyes Alte Boerse, Munich, Germany
| | | | - Jonathan Hall
- MVZ Prof. Neuhann GmbH, Helene-Weber-Allee 19, 80637, Munich, Germany
| | - Lukas Neuhann
- MVZ Prof. Neuhann GmbH, Helene-Weber-Allee 19, 80637, Munich, Germany
| | | |
Collapse
|
7
|
Identification of Treatment Protocols for Effective Cross-Linking of the Peripheral Cornea: An Experimental Study. Ophthalmol Ther 2022; 11:2057-2066. [PMID: 36066843 DOI: 10.1007/s40123-022-00564-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Accepted: 08/24/2022] [Indexed: 10/14/2022] Open
Abstract
INTRODUCTION This study aimed to test and evaluate modified corneal cross-linking (CXL) protocols regarding improved treatment effects on the peripheral cornea in terms of tissue stability and cellular response. METHODS Peripheral CXL (pCXL) was performed within a ring of 9-11 mm of 36 human donor corneas with variations in applied energy (5.4, 7.2, and 10 J/cm2) at 9 mW/cm2 irradiance. Each energy level was additionally modulated regarding the oxygen level surrounding the cornea during treatment (21%; 100%). Stress-strain tests with endpoints at 12% strain and collagenase A-assisted digestions to complete digestion were performed to evaluate the rigidity and resistance of treated and control tissue. Further, corneas were processed histologically via TUNEL assay and H&E staining to demonstrate the effects on stromal cells during treatment under varying CXL conditions. RESULTS Increases in energy dosage achieved significant increases in resistance to stress in all variations except when comparing protocols A and B under normoxic conditions. Supplemental oxygen significantly increased rigidity in protocols B (p < 0.01) and C (p = 0.018). Hyperoxic conditions significantly increased resistance to digestion in all protocols. The number of DNA strand breaks in TUNEL assay staining showed significant increases in all increases in energy as well as with oxygen supplementation. CONCLUSIONS Increases in energy and supplemental oxygen improved the effect of CXL, though endothelial safety could not be verified with confidence in high-fluence CXL with supplemental oxygen. Results suggest that CXL protocols using 7.2 J/cm2 with 100% O2 or 10 J/cm2 without supplemental oxygen prove most effective without anticipated risk of endothelial damage.
Collapse
|